Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Marial + omeprazole
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Administration
- Oral
01
Overview
**Marial + omeprazole** is a combination therapy used for the treatment of gastroesophageal reflux disease (GERD) and related conditions. Marial is a medical device formulation that typically includes magnesium alginate and the E-Gastryal complex (hyaluronic acid, hydrolyzed keratin, tara gum, xanthan gum, and purified water). It acts mechanically by forming a mucoadhesive film that adheres to the esophageal mucosa, providing a protective barrier against gastric acid, promoting healing, and reducing symptoms of acid reflux, heartburn, and mucosal injury. Omeprazole is a proton pump inhibitor (PPI), a small molecule drug that reduces gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme (proton pump) on gastric parietal cells. This combination targets rapid and effective symptom control through complementary mechanisms—mechanical protection (Marial) and acid suppression (omeprazole)—and is evaluated particularly for patients with persistent reflux symptoms despite standard PPI therapy[1][2][4][6].
- Brand names
- Marial + omeprazole
- Other names
- Marial + PPIMarial + generic omeprazole
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on Marial + omeprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Marial + omeprazole.